Takeda says FDA approved Alunbrig (brigatinib) as a first-line treatment option for patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC), a rare and serious form of lung cancer.
- The approval expands Alunbrig’s current indication to include the first-line setting
April 6, Takeda’s Alunbrig Approved by EC for ALK+ NSCLC Treatment
To view the source of this information click
To contact the reporter on this story:
To contact the editor responsible for this story:
© 2020 Bloomberg L.P. All rights reserved. Used with...